Companies /Healthcare

Veeva Systems Inc - Class A

NYSE: VEEV Health Information Services
$282.13
â–² $37.22 (+15.20%) today
Markets closed · 7:36pm ET

Q3 2026 Earnings

Reported Nov 20, 2025, 4:04pm ET · SEC source
$2.04
Beat +4.55%
EPS · est. $1.95
$811.2M
Beat +2.35%
Revenue · est. $792.6M
−13.3%
Trailing market
VEEV vs S&P since report
7 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−12%−8%−4%0Nov 20Nov 21report 4:04pm ETearnings+1.2%−9.6%
−12%−8%−4%0Nov 20Nov 21earnings+1.2%−9.6%
VEEV −9.6%S&P 500 +1.2%
−10%−5%0Nov 20Nov 21report 4:04pm ETearnings+1.1%−9.6%
−10%−5%0Nov 20Nov 21earnings+1.1%−9.6%
VEEV −9.6%NASDAQ +1.1%
−5%0+5%Nov 19Nov 28report 4:04pm ETearnings+4.8%−5.8%
−5%0+5%Nov 19Nov 28earnings+4.8%−5.8%
VEEV −5.8%S&P 500 +4.8%
−5%0+5%Nov 19Nov 28report 4:04pm ETearnings+5.9%−5.8%
−5%0+5%Nov 19Nov 28earnings+5.9%−5.8%
VEEV −5.8%NASDAQ +5.9%
−9.77%
Day of report
−3.41%
Next session
−1.50%
One week
−8.57%
30 days

S&P 500 over the same 30 days: +4.76%.

Did VEEV Beat Earnings? Q3 2026 Results

Veeva Systems posted a clean beat across the board in fiscal Q3 2026, reporting non-GAAP diluted EPS of $2.04 against a consensus estimate of $1.95 — a 4.55% beat — while revenue of $811.24 million topped expectations by 2.35% and grew 16% year over year. The primary engine behind the quarter was subscription services, which climbed 17% to $682.50 million, with particular strength in both the Commercial and R&D Solutions segments as three top-20 biopharmas designated Veeva Development Cloud applications as their enterprise standard during the period. Non-GAAP operating margin expanded to 45.0% from 43.5% a year ago, reflecting disciplined cost management even as R&D spending increased to support the company's Veeva AI initiative — early AI agents for CRM and commercial content are on track for December release. Management raised full-year fiscal 2026 revenue guidance to approximately $3.17 billion and non-GAAP EPS to $7.93, keeping the company's longer-term $6 billion revenue run-rate target for 2030 firmly in view. Notably, free cash flow of $1.4 billion significantly exceeded statutory profit, suggesting the underlying earnings quality is stronger than headline figures alone imply.

Key Takeaways
  • Subscription services revenue growth of 17% year over year driven by both Commercial and R&D Solutions
  • Vault CRM momentum with 23 new customer additions and 115 total customers live
  • Development Cloud enterprise standard wins at three top 20 biopharmas
  • Non-GAAP operating margin expansion to 45.0% from 43.5% year over year
  • Broad-based strength across the business leading to raised full-year guidance

“Continuing to lead through innovation, Veeva AI delivers on our vision for industry-specific AI that will help the life sciences industry reach new levels of productivity and customer centricity.”

Veeva Systems CEO, on the earnings call

Forward Guidance & Outlook

For fiscal Q4 2026 (ending January 31, 2026), Veeva guided total revenues of $807–$810 million, non-GAAP operating income of approximately $350 million, and non-GAAP fully diluted net income per share of approximately $1.92. For full fiscal year 2026, guidance was raised to total revenues of $3,166–$3,169 million, non-GAAP operating income of approximately $1,417 million, and non-GAAP fully diluted net income per share of approximately $7.93. The company reaffirmed its 2030 target of a $6 billion revenue run rate.

VEEV YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$300.0M$600.0M$699.2M$811.2MRevenue$524.8M$611.8MGross Profit$181.4M$240.9MOperating Income$185.8M$236.2MNet Income
$0$300.0M$600.0MRevenueGross ProfitOperating IncomeNet Income

VEEV Revenue by Segment

Subscription Services$682.5M+17.0%
Veeva R&D Solutions - Subscription$364.8M
Veeva Commercial Solutions - Subscription$317.7M
Professional Services and Other$128.7M
Veeva R&D Solutions - Professional Services$81.3M
Veeva Commercial Solutions - Professional Services$47.5M

Figures from SEC filings and company reports. Not investment advice.